[A 2022 inventory in oncology news].

Que retenir dans la prise en charge des cancers en 2022 ?
Actualités 2022 en cancérologie New treatments in oncology Nouveaux traitements Updates in 2022

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Jan 2023
Historique:
received: 01 12 2022
accepted: 05 12 2022
pubmed: 19 12 2022
medline: 14 1 2023
entrez: 18 12 2022
Statut: ppublish

Résumé

The Cancer Bulletin continues its tradition. At the beginning of 2023, the members of the editorial committee would like to share with you their analyses of the highlights of 2022. The objective remains to highlight what will change our practices and lead to different diagnostic or therapeutic options. Our synthesis will therefore focus on published data. They have been analyzed and placed in the more general context of the management of each type of cancer to deduce the practical consequences for our patients. This synthesis exercise will concern almost all tumor pathologies, most often on the therapeutic level, and will, however, exclude the evolution of techniques, whether they are diagnostic or used for the follow-up of our patients. The final objective is to allow you to have a thoughtful, didactic and practical reading. Our goal is to provide our readers with the rational bases that can lead to a different approach for treatments in 2023.

Identifiants

pubmed: 36529541
pii: S0007-4551(22)00437-4
doi: 10.1016/j.bulcan.2022.12.002
pii:
doi:

Types de publication

English Abstract Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

19-31

Informations de copyright

Copyright © 2022. Published by Elsevier Masson SAS.

Auteurs

Jacques-Olivier Bay (JO)

CHU de Clermont-Ferrand, service de thérapie cellulaire et d'hématologie clinique adulte, UE7453 CHELTER, Inserm CIC-501, site Estaing, 63000 Clermont-Ferrand, France. Electronic address: jobay@chu-clermontferrand.fr.

Carole Bouleuc (C)

Sorbonne université, Paris, France; Institut Curie, département de soins de support, 26, rue d'Ulm, 75005 Paris, France.

Christophe Caux (C)

Université Claude-Bernard Lyon 1, CNRS 5286, centre de recherche en cancérologie de Lyon, Inserm U1052, 69008 Lyon, France.

Frédéric Delom (F)

University Bordeaux, ARTiSt Lab, Inserm U1312, 33000 Bordeaux, France.

Nelly Firmin (N)

Université Montpellier, ICM Montpellier, IRCM, Inserm U1194, 208, avenue des apothicaires, 34298 Montpellier, France.

Virginie Gandemer (V)

CHU de Rennes, service d'hémato-oncologie pédiatrique, 35000 ReDnnes, France.

Gilles L'Allemain (G)

Université Côte d'Azur, CNRS, Inserm, institut biologie Valrose, 06108 Nice, France.

Nicolas Magné (N)

Institut Bergonie, département de radiothérapie, Bordeaux, France.

Daniel Orbach (D)

PSL université, institut Curie, centre intégré de soins et de recherche en oncologie de l'enfant, adolescent et jeune adulte (SIREDO), 26, rue d'Ulm, 75005 Paris, France.

Jacques Robert (J)

Université de Bordeaux, Inserm U1218, 33000 Bordeaux, France.

Manuel Rodrigues (M)

PSL Research University, institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.

Renaud Sabatier (R)

Aix-Marseille université, CNRS, institut Paoli-Calmettes, département d'oncologie médicale, Inserm, Marseille, France.

Antoine Thiery-Vuillemin (A)

CHRU Jean-Minjoz, department of medical oncology, 25030 Besançon cedex, France; Université de Franche-Comté, SFR IBCT, Inserm U1098, 25020 Besançon cedex, France.

Marie Wislez (M)

AP-HP Centre, hôpital Cochin, service de pneumologie, unité d'oncologie thoracique, 75000 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH